EP2210891A1 — New adenosine receptor ligands and uses thereof
Assigned to Domain Therapeutics SA · Expires 2010-07-28 · 16y expired
What this patent protects
The present invention provides new compounds with high affinity for adenosine A 2A receptors. It also provides antagonists of adenosine A 2A receptors and their use as medicaments for the treatment and/or prophylaxis of diseases and disorders where the partial or total inactiva…
USPTO Abstract
The present invention provides new compounds with high affinity for adenosine A 2A receptors. It also provides antagonists of adenosine A 2A receptors and their use as medicaments for the treatment and/or prophylaxis of diseases and disorders where the partial or total inactivation of adenosine A 2A receptors signalling pathways could be beneficial such as Alzheimer's disease, Parkinson's disease, attention deficit and hyperactivity disorders (ADHD), Huntington's disease, neuroprotection, schizophrenia, anxiety and pain. The present invention further relates to pharmaceutical compositions containing such new compounds with high affinity for adenosine A 2A receptors and their use for the treatment and/or prophylaxis of diseases and disorders where the partial or total inactivation of adenosine A 2A receptors could be beneficial.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.